Staged Chemically Defined Pericyte Differentiation From PSCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for differentiating pericytes from pluripotent stem cells are complex, non-standardized, and result in low purity and efficiency, often indistinguishable from smooth muscle cells or mesenchymal stem cells, making it difficult to reproduce and integrate with organoid models.
Innovation Solution
A chemically defined differentiation protocol using E8 medium supplemented with BMP4, activin, GSK-3 inhibitor, and subsequent EGM2 medium with transferrin, insulin, FGF2, VEGF-A, and TGFβ1 inhibitor, allowing for the isolation and culture of CD34− or CD31− cells, which express pericyte markers PDGFRβ, SM22, and Desmin, achieving a pure pericyte population in 8-12 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional methods are used to differentiate pericytes from pluripotent stem cells, then pericyte differentiation can be achieved, but the process is complex, non-standardized, and results in low purity and efficiency
Solution Approach 1:
The differentiation protocol is divided into distinct temporal stages with specific media compositions: Stage 1 (days 0-2) uses E8 medium with BMP4, activin, and GSK-3 inhibitor for initial mesoderm induction; Stage 2 (days 3-6) transitions to EGM2 medium with transferrin, insulin, FGF2, VEGF-A, and TGFβ1 inhibitor for pericyte specification; Stage 3 (days 7-12) uses EGM2 medium with pericyte markers for maturation. This segmentation allows optimization of each differentiation phase independently, achieving high purity (≥95%) while maintaining protocol standardization through defined media recipes.
Solution Approach 2:
The protocol systematically changes chemical parameters (media composition, growth factor concentrations, inhibitor dosages) at specific temporal points to drive differentiation. Key parameter transitions include: adding BMP4 (5-15 ng/ml) and activin (10-30 ng/ml) at day 0; introducing GSK-3 inhibitor (1-5 μM) at day 0; switching to EGM2 medium with specific concentrations of transferrin (5-15 μg/ml), insulin (10-30 μg/ml), FGF2 (70-150 ng/ml), VEGF-A (25-75 ng/ml), and TGFβ1 inhibitor (2-10 μM) at day 3. These controlled parameter changes enable reproducible, high-purity pericyte generation.
2Productivity
If traditional differentiation methods are used, then pericyte isolation is possible, but the process is time-consuming and inefficient
Solution Approach 1:
The protocol performs preliminary actions by pre-establishing the correct media composition and growth factor supplementation before differentiation begins. Stage 1 media (E8 with BMP4, activin, GSK-3 inhibitor) is prepared in advance to induce proper mesoderm formation, which sets up the cells for efficient pericyte differentiation in subsequent stages. This preliminary preparation eliminates trial-and-error adjustments during the differentiation process, accelerating the overall timeline to 8-12 days while maintaining high efficiency.
Solution Approach 2:
The differentiation protocol maintains continuous useful action through uninterrupted cell culture and media exchange. Cells are cultured continuously from day 0 to day 12 with daily or every-other-day media changes according to the staged protocol. The transition from E8 medium to EGM2 medium is seamless, and pericyte markers are detected continuously. This continuous process without idle periods or repeated passaging maximizes productivity while achieving ≥95% purity.
3Reliability
If existing differentiation protocols are used, then pericytes can be generated, but they are difficult to reproduce and integrate with organoid models
Solution Approach 1:
The protocol establishes standardized chemical parameters through defined media recipes with specific concentrations: E8 medium with BMP4 (5-15 ng/ml), activin (10-30 ng/ml), and GSK-3 inhibitor (1-5 μM) for Stage 1; EGM2 medium with transferrin (5-15 μg/ml), insulin (10-30 μg/ml), FGF2 (70-150 ng/ml), VEGF-A (25-75 ng/ml), and TGFβ1 inhibitor (2-10 μM) for Stages 2-3. These standardized parameters enable precise reproduction across different laboratories and time points, facilitating integration with organoid models that require consistent pericyte characteristics.
Solution Approach 2:
The differentiated pericytes exhibit multi-functionality suitable for various applications: they express characteristic markers (PDGFRβ, SM22, CD13, Desmin) for identification, form stable associations with endothelial cells in 3D vasculature, and can be used in disease modeling, drug screening, and therapeutic contexts. The protocol's standardized approach produces universal pericyte populations that can be integrated with different organoid models and experimental systems, enhancing reliability and ease of manufacture.
Data Source
AI summary
The present invention provides methods of differentiating pericytes from pluripotent stem cells comprising culturing steps in chemically defined culture medium. A population of exogenously derived pericytes from PSCs are also contemplated. Further uses of the exogenously cultured pericytes for an in vitro disease model or in vitro angiogenesis assay are contemplated, including an in vitro 3D model of vasculature.